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ABSTRACT
Integration of retroviral DNA into the host chromosome
requires the integrase protein (IN). We overexpressed
the IN proteins of human immunodeficiency viruses
types 1 and 2 (HIV-1 and HIV-2) in E. coli and purified
them. Both proteins were found to specifically cut two
nucleotides off the ends of linear viral DNA, and to
integrate viral DNA into target DNA. This demonstrates
that HIV IN is the only protein required for integration
of HIV DNA. Although the two types of IN proteins have
only 53% amino acid sequence similarity, they act with
equal efficiency on both type 1 and type 2 viral DNA.
Binding of IN to DNA was tested: purified IN does not
bind very specifically to viral DNA ends. Nevertheless,
only viral DNA ends are cleaved and integrated. We
interpret this as follows: in vitro quick aspecific binding
to DNA is followed by slow specific cutting and
integration. IN can not find viral DNA ends in the
presence of an excess of aspecific DNA; in vivo this
is not required since the IN protein is in constant
proximity of viral DNA in the viral core particle.
INTRODUCTION
Acquired Immunodeficiency Syndrome (AIDS) is caused by
HIV-1 or HIV-2. HIV-1 is widespread, whereas HIV-2 is
primarily found in West-Africa. Although both viruses have only
limited sequence similarity (42% on the nucleotide level), they
cause a disease with similar symptoms. HIV-2 is more related
to simian immunodeficiency virus (SIV) than to HIV-1 (1).
An essential step in the retroviral lifecycle is the integration
of a double stranded DNA copy of the viral genomic RNA into
the host genome. From studies of retroviral integration in vitro
the following picture of the reaction has emerged (reviewed in
2). The 3' terminal two nucleotides are removed from both ends
of the double-stranded linear viral DNA (3-6). Subsequently,
target DNA is cut in a staggered fashion, which leaves 5'
protruding ends, and the 3' ends of the viral DNA are ligated
to the 5' protrusions of the target DNA (7, 8). This reaction does
not require ATP. It is not yet clear whether there is a covalent
intermediate between integrase (IN) and the target DNA or
whether cleavage of the target DNA and ligation to the viral DNA
are accomplished in a concerted reaction. In vivo the remaining
single-stranded gaps are then filled in, probably by cellular repair
enzymes, which results in a target DNA duplication.
One retroviral protein is required for the integration reaction:
IN. Mutations in the IN coding region of the pol gene result in
retroviruses that are defective in integration (9, 10). Various
assays have been developed to test for activities of (partially)
purified IN protein. IN proteins of several retroviruses have been
shown to be able to cut off two nucleotides from the 3' end of
double-stranded oligonucleotides that mimic the viral DNA ends
(6, 11, 12). In the same assay, integration of one oligonucleotide
into another was observed (3, 4, 13-16). IN has only limited
substrate specificity: most point mutations in the viral DNA do
not severely affect specific cleavage and integration (14, 17), and
the IN protein of Moloney murine leukemia virus (MoMLV) can
mediate integration of DNA substrates with HIV DNA ends (13,
18). Probably IN function does not require much specificity, since
IN remains in the viral core particle when the double-stranded
DNA copy is synthesized, and it does not need to search a whole
cellular genome for its specific viral sites (19, 20).
Although it has been established that partially purified HIV
IN can carry out the integration reaction, it had not been excluded
that contaminating host proteins are essential for the reaction.
The IN protein of avian sarcoma leukosis virus, judged to be
pure on a coomassie stained gel, is sufficient for integration in
vitro (4), and by analogy one would expect that pure IN would
also be sufficient for integration of mammalian retroviruses such
as HIV. In this study we addressed this by determining the activity
of purified HIV-1 and HIV-2 IN.
We studied the IN proteins of both HIV types for the following
reasons:
1. The similarity between the IN proteins of HIV-1 and HIV-2
is 57%; the sequences of their viral DNA substrates differ in
3 out of 15 positions at the U3 end and in 2 out of 15 positions
at the U5 end. In search for sequence specific DNA recognition
domains, we tested whether the IN proteins of HIV-1 and HIV-2
prefer to bind and cleave their cognate viral DNA ends over those
of the other.
2. In vitro assays for IN activity can be used to screen, test
and improve drugs that may interfere with this reaction and have
therapeutic potential. It will be important to check that these drugs
act on the IN proteins of both HIV types.
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In order to mediate viral integration, IN has to recognize viral
DNA ends specifically and target DNA aspecifically. General
DNA binding has been detected for the IN proteins of several
retroviruses in South-Western assays and filter binding assays
(6, 21-25). Also specific binding of MoMLV IN to the viral
DNA ends in a South-Western assay was reported (26). The IN
proteins ofMoMLV and HIV-1 were reported to bind specifically
to viral DNA termini in a mobility shift assay (27 -29). Using
purified and active HIV-1 and HIV-2 IN we found quite different
results: IN has only an approximately three-fold preference for
specific viral sequences over aspecific DNA. Following quick
aspecific binding IN cuts and mediates integration only when it
encounters viral substrate sequences.
MATERIALS AND METHODS
Materials
Restriction enzymes, T4 DNA ligase and T4 polynucleotide
kinase were purchased from Boehringer Mannheim. Taq
polymerase was purchased from Perkin Elmer Cetus,
radiochemicals from Amersham.
DNA techniques
Standard DNA techniques were carried out as described (30).
The HIV-1 IN expression vector (pRP 274) is essentially the same
as the one described by Sherman and Fyfe (6), and is described
in detail by Vink et al. (17). The HIV-2 IN expression plasmid
was constructed as follows. The IN coding region of HIV-2 (clone
pROD4.8, kindly provided by M. Emerman; ref. 1) was
amplified by PCR, using oligonucleotides 5'-TTTCATATGTT-
CCTGGAAAAAATAGAGCCC-3' and 5'-TTTAGATCTAT-
GCCATTTCTCCATCC-3' as primers. The resulting PCR
product had a NdeI site at the 5' end, and a BglII site at the 3'
end of the IN coding region. By digesting the PCR product with
NdeI and BglIH and cloning the resulting fragment into the NdeI
and BamHI digested pET-3c expression vector (31), the IN gene
was placed under transcriptional control of the bacteriophage T7
promoter. In the resulting construct (pRP 279) an ATG translation
initiation codon precedes the TTC triplet, encoding the N-terminal
phenylalanine of HIV-2 IN. E. coli BL21(DE3), which carries
the T7 RNA polymerase gene under control of the lacUV5
promoter, was used as host bacterium.
Protein production and purification
Bacteria expressing either the HIV-1 or the HIV-2 IN gene were
grown overnight in LB medium supplemented with 50 ptg/ml
ampicillin. The o/n culture was diluted 1:50 in 1 liter TB medium
(30) supplemented with 10 mM MgSO4, 50 itg/ml ampicillin
and grown for 4 hours at 37°C. IN expression was started by
addition of isopropyl ,3-D-thiogalactopyranoside (IPTG) to a final
concentration of 0.3 mM. Three hours after induction cells were
collected by centrifugation and resuspended in 40 ml ice-cold
lysis buffer (50 mM Tris.HCl, pH 7.5, 5 mM dithiothreitol
(DTT), 1 mM EDTA, 1 mg/ml lysozyme) and incubated at 0°C
for 15 minutes. After sonication of the cells, we followed the
same procedure as described by Sherman and Fyfe for
purification of HIV-1 IN (6). For the purification of HIV-2 IN
we modified the procedure as follows. The 1 M NaCl extract
was dialyzed for 2 hours against buffer 1 (50 mM Tris.HCl, pH
7.5, 0.5 M ammonium sulfate, 0.4 M NaCl, 5 mM DTT, 0.1
mM EDTA). After centrifugation (20 minutes, 10.000 x g) the
supernatant was loaded onto a Butyl-Sepharose 4B (Pharmacia)
column of 10 ml, equilibrated with buffer 1. After washing the
column with 75 ml buffer 1, elution was started with a linear
gradient from buffer 1 to buffer 2 (50 mM Tris.HCl, pH 7.5,
100 mM NaCl, 5 mM DTT, 10% (vol/vol) glycerol). The
gradient (100 ml) was followed by 50 ml buffer 2. The integrase
containing fractions (detected by SDS-PAGE analysis) were
pooled and diluted with 1 volume buffer 3 (50 mM Tris.HCl,
pH 7.5, 5 mM DTT, 10% (vol/vol) glycerol) before loading onto
the Heparin-Sepharose CL-6B (Pharmacia) column. The protein
was eluted from this column as described by Sherman and Fyfe
(6). The HIV-1 IN preparation contained 30 ng of protein per
itl and the HIV-2 IN preparation 100 ng/Id in buffer 3 containing
750 mM NaCl. Batches of integrase-containing fractions were
frozen in liquid nitrogen and stored at -70°C.
Gel exclusion chromatography
A 180 ml Sephacryl S-300 HR (Pharmacia) column was
equilibrated with 20 mM TRIS.HCl, pH 7.5, 1 M NaCl, 1 mM
DTT and calibrated with Blue Dextran 2000, Bovine serum
albumin, Ovalbumin, and Chymotrypsinogen A (sizemarkers
purchased from Pharmacia). Proteins were detected by
continuously monitoring the OD280 of the flow through. The
position of IN was visualized by SDS-PAGE.
SDS-PAGE analysis
Protein samples were subjected to electrophoresis in 10% SDS-
polyacrylamide minigels (Biorad) and visualized by either
coomassie brilliant blue staining or silver staining (silver stain
kit, purchased from Sigma). To obtain increased sensitivity, the
silver staining procedure was done twice (as described by the
supplier).
Cleavage and integration reactions
For the cleavage and integration reactions the following double-
stranded oligonucleotide substrates were used: 28-mers
representing the HIV-l U5 (5' TTAGTCAGTGTGGAAAAT-
CTCTAGCAGT-3' and the complementary strand) and U3 ends
(5'-TCGTTGGGAGTGAATTAGCCCTTCCAGT-3' and the
complementary strand, sequence from ref. 32), the HIV-2 U5
(5'-AAACCGAGGCAGGAAAATCCCTAGCAGG-3' and the
complementary strand) and U3 ends (5 '-TCTTTCA-
CTGTAAAACATCCCTTCCAGT-3' and the complementary
strand, sequence from ref. 1) and the MoMLV U5 end
(5'-GACTACCCGTCAGCGGGGGTCTTTCATT-3' and the
complementary strand, sequence from ref. 33). Also aspecific
double-stranded oligonucleotides were used (5'-GCGTGTATG-
AATCCGTCGAGAGCTACTA-3' and the complementary
strand). The strands of which the sequence is given were labeled
using ['y-32P]-ATP and T4 polynucleotide kinase. Full length
oligonucleotides were isolated from a 12% denaturing
polyacrylamide gel, and resuspended in TE (10 mM Tris.HCl,
pH8, 1 mM EDTA) to a final concentration of 0.2 pmoles/4l,
mixed with a 4-fold excess of the unlabeled complementary
strand, heated to 80°C and allowed to anneal by slow cooling
to room temperature.
The cleavage and integration reactions were carried out
essentially as described for MoMLV IN (7). The standard
reaction mixture contained 20 mM MOPS pH 7.2, 75 mM NaCl,
10 mM DTT, 20% glycerol (v/v), 100 ,g/ml bovine serum
albumin, 3 mM MnCl2 (HIV-1) or 1 mM MnCl2 (HIV-2), 0.2
pmoles of labeled double-stranded LTR substrate and 1 pmol
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HIV-l IN or 3 pmoles HIV-2 IN in a total volume of 10 A1. For
the competition studies equal amounts of both strands of the
competitor DNA were mixed, heated to 80°C and allowed to
anneal by slow cooling to room temperature. The reaction
mixtures were incubated for one hour at 30°C.
Reactions were stopped by addition of 10 Al 95% formamide,
20 mM EDTA, 0.05% bromophenol blue and 0.05% xylene
cyanol. Samples were heated to 80°C for 2 minutes and 5 ,tl
samples were analyzed on 12% denaturing polyacrylamide gels
in 1 x TBE (30). Gels were dried and reaction products were
visualized by autoradiography. To quantitate the reaction, cleaved
and uncleaved products were excised from the gel. Gelslices were
incubated overnight in scintillation cocktail (Ultima Gold,
Packard) and their radioactivity was determined in a scintillation
counter.
Mobility shift assay
Binding reactions were performed under the same conditions as
the cleavage reactions or under conditions that were essentially
the same as described for HIV-1 IN binding (29): 25 mM
HEPES, pH 7.5, 75 mM NaCl, 5 mM MgCl2, 1 mM DTT, 5%
glycerol (v/v), 0.4 pmoles of double-stranded oligonucleotide and
2 pmoles of HIV-l IN or 6 pmoles of HIV-2 IN in a total volume
of 20 ltl. Reaction mixtures were incubated for 15 minutes at
30°C (which are the conditions of the cleavage reaction) or for
10 minutes at room temperature. The glycerol concentration was
adjusted to 20% and the samples were separated in 6%
polyacrylamide gels in 1/2 xTBE at room temperature (5V/cm).
Gels were dried and products were visualized by autoradiography.
As shown in figure 2, HIV-1 and HIV-2 IN have similar substrate
preferences: they both act on HIV-1 and HIV-2 substrates with
equal efficiency. For both IN proteins U5 is a somewhat better
substrate than U3. However, the U5 end of MoMLV, a more
distantly related retrovirus with DNA ends that differ significantly
from HIV DNA ends (8 out of 15 nucleotides are similar at the
U3 end and 6 out of 15 at the U5 end), was cleaved with much
lower efficiency than HIV DNA ends, and no integration products
were detected (figure 2 lanes 14 and 15), not even after long
exposure times (not shown). HIV-2 IN cleaved the MoMLV
substrate primarily at the expected position, 3' of the conserved
CA sequence. Since there is some aspecific nuclease activity in
the HIV-l IN preparation, no specific cutting ofMoMLV DNA
ends could be detected above the background.
In this assay also products were formed, that were longer than
the substrate (figure 2 lanes 6 and 12). It has previously been
shown, that those are the result of integration of one
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RESULTS
Overexpression and purification of HIV-1 and HIV-2 IN
The IN coding regions of HIV-1 and HIV-2 were cloned behind
the T7 promoter and an ATG initiation codon in the expression
vector pET-3c. Both proteins were overproduced and purified
essentially as described (6), with some modifications (see
materials and methods). Figure lA shows an SDS-PAGE analysis
of a total cell lysate of HIV-2 IN expressing E. coli cells (lane
2), proteins solubilized in IM NaCl (lane 3) and purified HIV-2
IN (lane 4). On a silver stained gel (figure iB) the HIV-2 IN
preparation appears to be pure; HIV-1 IN contains some minor
contaminants. The yield of protein from one liter of E. coli culture
was approximately 0.3 mg for HIV-l IN and 1 mg for HIV-2 IN.
The subunit stoichiometry of HIV-1 IN and HIV-2 IN in
solution (containing IM NaCl) was determined by gel exclusion
chromatography. Both proteins eluted between ovalbumin and
chymotrypsinogen A, corresponding to a MW of approximately
32 kD, as expected for IN monomers (figure IC). At lower salt
concentration the proteins precipitate out of solution (see below).
Activities of HIV-2 IN
HIV-l IN can specifically cleave the ends of viral DNA and
integrate viral DNA substrates into target DNA (6, 14, 17).
HIV-2 IN was tested for the same activities. As shown in figure
2 (lanes 9 and 12), purified HIV-2 IN was able to cut off two
nucleotides from the 3' end of oligonucleotide substrates that
represent the HIV-2 DNA ends. We investigated whether the
IN proteins of HIV-l and HIV-2 recognize each others substrates
and whether they have a preference for their own DNA ends.
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Figure 1. HIV integrase proteins. (A) Purification of HIV-2 IN. Total E. coli
cell lysate (lane 2), IM NaCI supernatant (lane 3) and purified HIV-2 IN (lane
4). Lane 1 contains marker proteins: rabbit muscle phosphorylase b (97.4 kD),
bovine serum albumin (66.2 kD), hen egg white ovalbumin (42.7 kD), bovine
carbonic anhydrase (31 kD), soybean trypsin inhibitor (21.5 kD) and hen egg
white lysozyme (14.4 kD). The gel was stained with coomassie brilliant blue.
(B) Silver stained gel with purified HIV-2 IN (lane 2) and HIV-1 IN (lane 3).
Lane 1 contains the same marker proteins as in (A). The faint bands around the
position of 60 kD are not proteins in the sample, but contaminants that are present
in the sample buffer. (C) Gel exclusion chromatography of IN. Elution volume
is plotted against log(MW). The positions of the main peaks of HIV-1 and HIV-2
IN are marked with a triangle and a circle respectively. For HIV- I IN very faint
peaks were detected at the predicted dimer position (elution volume of 90 mi)
and in the void volume (60 ml). The pluses indicate proteins with known MW.
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oligonucleotide into another (3, 4, 14). Note that integrations are
more frequent near the ends of an oligonucleotide than in the
central region (figure 2, lanes 6 and 12). Moreover, integration
patterns are somewhat different for the various substrates
(compare lanes 5, 8 and 11) and they are somewhat different
for HIV-1 and HIV-2 IN (compare lanes 5 and 6), indicating
that under these conditions integration is non-random. The
significance for target preference in vivo (34) remains to be
Figure 2. Cleavage and integration of oligonucleotide substrates. Cleavage
reactions were performed on double-stranded 28-mer oligonucleotides that represent
HIV-1 U3 (lanes 1-3), HIV-1 U5 (lanes 4-6), HIV-2 U3 (lanes 7-9), HIV-2
U5 (lanes 10-12) and MoMLV US ends (lanes 13- 15). Reactions were carried
out without IN (lanes 1, 4, 7, 10 and 13), with HIV-1 IN (lanes 2, 5, 8, 11 and
14) or with HIV-2 IN (lanes 3, 6, 9, 12 and 15). The samples were separated
on a 12% denaturing polyacrylamide gel. A protein preparation was also purified
from cells that harbor only the expression vector pET-3c, in the same way as
HIV-1 IN. The same reactions were carried out with this protein preparation.
It did not contain nuclease activity (results not shown). The arrows indicate the
positions of the uncleaved (28) and cleaved (26) oligonucleotides, IP = integration
products.
A
determined. Since this is the first reported case of activity of pure
HIV IN we can now conclude that IN is the only protein required
for HIV integration in vitro. We can however not rule out the
possibility that host proteins enhance the efficiency of the reaction.
In the standard cleavage reaction with HIV-2 IN the protein
to DNA ratio is 15: 1 on a molar basis. Under these conditions
only 30-50% of the substrate was cleaved. Possibly the reaction
is very slow. We therefore investigated the kinetics of the
cleavage reaction. As shown in figure 3A the reaction rate was
constant for approximately 20 minutes and thereafter decreased.
Between one and two hours after start of the reaction some
additional cleavage occurred, but the amount of cleaved product
did not increase significantly at longer reaction times (results not
shown). With a four-fold lower substrate concentration a
comparable curve was obtained for the time course (figure 3A),
showing that the decrease in reaction rate is independent of the
concentration of substrate or product. The level of cleavage was
linear with IN concentration (figure 3B) and not with substrate
concentration (figure 3C), supporting the conclusion that the
amount of IN is rate limiting in this assay. The incomplete
conversion of substrate to cut product can be explained by slow
inactivation, probably due to aggregation and precipitation of IN
(see below).
Competition of the cleavage reaction
The cutting and integration reaction is sequence specific: only
linear DNA with a specific viral sequence at its end can be cut
and integrated. This implies that IN specifically recognizes these
sequences. We investigated whether this specific recognition
could be outcompeted by an excess of DNA of aspecific as well
as specific sequence. As shown in figure 4A (lanes 3-6) the
cleavage reaction was strongly competed by oligonucleotides that
mimic the HIV-1 U5 as well as U3 DNA ends. Surprisingly,
MoMLV DNA ends, and even a double-stranded 28-mer
oligonucleotide of a sequence unrelated to viral DNA ends, also
competed in the cleavage reactions (figure 4A lanes 7-10). The
aspecific oligonucleotides competed approximately three-fold less
strongly than specific competitors (as determined by counting
radioactivity in excised gelslices).
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Figure 3. The cleavage reaction. (A) Timecourse of the cleavage reaction. The amount of cleaved product (as percentage of the total amount of substrate) is plotted
against incubation time for the reaction with 0.05 pmoles (pluses) and 0.2 pmoles of HIV-1 US substrate per 10 ytl (triangles). (B) 0.02 pmoles of US substrate
per ,ul was incubated for one hour with HIV-2 IN. The amount of cleaved product (as percentage of the total amount of substrate) is plotted against the IN concentration.
(C) 3 pmoles of HIV-2 IN were incubated with 50 (lane 1), 72 (lane 2), 140 (lane 3), and 500 (lane 4) fmoles of HIV-1 US substrate. The samples were separated
on a 12% denaturing polyacrylamide gel. Above the lanes the substrate concentration in fmoles per ttl is indicated.
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Since efficient cleavage requires that the specific viral DNA
sequence is present near the end of linear DNA (17), we tested
whether DNA ends are required for competition in the cutting
reaction. As shown in figure 4A (lanes 11) this is not the case:
circular pBR322 competes at least as strongly as oligonucleotides
(when the same mass of DNA is added). This shows that large
circular as well as small linear double-stranded DNA can inhibit
the cleavage reaction. We tested whether DNA needs to be
double-stranded. As shown in figure 4B single-stranded DNA
did not compete as efficiently as double-stranded DNA. To obtain
the same level of competition approximately 15 times more single-
stranded than double-stranded DNA is needed (data not shown).
tRNA could also inhibit the cleavage reaction. It competed
approximately as efficiently as double-stranded DNA (figure 4A
lanes 13 and 14). We conclude, that cleavage by HIV IN can
be competed by aspecific double stranded DNA and by tRNA,
and (much less efficiently) by single-stranded DNA. How can
aspecific nucleic acids prevent sequence specific cutting by IN?
An explanation could be that IN quickly binds to nucleic acids
without much sequence specificity, and then (slowly) finds and
cuts specific viral sequences. To investigate this further we studied
binding of HIV IN to DNA.
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Figure 4. Competition of the cleavage reaction. (A) 0.05 pmoles of HIV-1 U5
substrate was incubated without IN (lane 1), with 3 pmoles of HIV-2 IN (lane
2) or with 3 pmoles of HIV-2 IN and as competitor DNA oligonucleotides that
mimic the HIV-1 U5 ends (lanes 3 and 4), the HIV-1 U3 ends (lanes 5 and 6),
or the MoMLV U5 ends (lanes 7 and 8), aspecific double-stranded 28-mer
oligonucleotides (lanes 9 and 10), pBR322 (lane 11), or yeast tRNA (lane 12).
Competition experiments were done with a 5-fold (lanes 3, 5, 7 and 9) or a 20-fold
(lanes 4, 6, 8 and 10-12) mass excess of competitor DNA or RNA. (B) Reactions
as in (A) without IN (lane 1), with HIV-2 IN (lane 2), or with HIV-2 IN and
a 20-fold mass excess of double-stranded US substrate (lane 3), single strands
of the US substrate (lanes 4 and 5), double-stranded aspecific 28-mer
oligonucleotide (lane 6), or single strands of the aspecific 28-mer (lanes 7 and
8). All competitor preparations were heated to 80°C and allowed to anneal by
slow cooling.
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Figure 5. DNA binding of HIV-I and HIV-2 IN. (A) Analysis of cleavage of
oligonucleotides representing the HIV-1 U5 end. 0.2 pmoles of the HIV-1 U5
substrate was incubated for 15 minutes under cleavage conditions without IN (lane
1), with 2 pmol HIV-l IN (lanes 2-8), or with 6 pmoles HIV-2 IN (lanes 9-15)
in 20 yd. The reaction mixtures were incubated for 15 minutes at 30°C without
competitor (lanes 1, 2 and 9), or with a 20-fold (lanes 3, 5, 7, 10, 12 and 14)
or a 100-fold (lanes 4, 6, 8, 11, 13, 15) excess of HIV-1 U5 substrate (lanes
3, 4, 10 and 11), MoMLV U5 substrate (lanes 5, 6, 12 and 13), or an aspecific
double-stranded 28-mer oligonucleotide (lanes 7, 8, 14 and 15). Samples were
separated on a 12% denaturing polyacrylamide gel. (B) Mobility shift gel with
the same reaction mixtures. Lanes 1-15 correspond to lanes 1-15 in (A). (C)
0.05 pmoles of HIV-1 U5 substrate were incubated without IN (lanes 1 and 2),
with HIV-2 IN (lanes 3 and 4), with HIV-2 IN and a 20-fold mass excess of
HIV-1 U5 ends (lanes 5 and 6), HIV-1 U3 ends (lanes 7 and 8), MoMLV U5
ends (lanes 9 and 10), aspecific double-stranded 28-mer oligonucleotides (lanes
11 and 12), pBR322 (lanes 13 and 14), or yeast tRNA (lanes 15 and 16). After
one hour incubation, the reactions were centrifuged for 30 minutes at 10,000 xg.
Lanes labeled 'S' contain supematants and lanes labeled 'P' contain pellets.
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Lack of specific binding of HIV-1 and HIV-2 IN to HIV DNA
ends
For the IN proteins of MoMLV and HIV-1 specific binding to
viral DNA ends was reported (26 -29). We investigated binding
of HIV-1 and HIV-2 IN to the HIV-1 U5 end in a mobility shift
assay. HIV-1 U5 oligonucleotides were incubated with HIV-1
or HIV-2 IN under the conditions used in the cleavage reaction;
part of the reaction mixture was analyzed on a denaturing
polyacrylamide gel to test whether IN was active in the cleavage
reaction (figure 5A), and part was analyzed on a mobility shift
gel (figure SB). Although we observed efficient cleavage, only
minor shifted bands were detected. Those bands were competed
equally well by both viral and aspecific DNA (figure SB, lanes
3-8). As shown in figure 5B (lane 9) HIV-2 IN does not produce
a strong band shift even in the absence of competitor; HIV- 1
IN, which contains some impurities, shows a stronger aspecific
band shift, and we conclude this is probably caused by
contaminants. We also performed mobility shift assays under the
slightly different conditions described by Leavitt et al. (29); again
faint bands were detected, and they were all competed away by
aspecific DNA (results not shown). We did not observe specific
cleavage under these conditions. We conclude that specific
binding of pure and active HIV IN to HIV DNA ends can not
be detected in a mobility shift assay under the conditions used.
An explanation for the absence of specific band shifts might
be, that DNA binding of HIV IN is specific, but not detectable
in a mobility shift assay. We therefore studied binding of IN to
DNA in a different way. We took advantage of our observation
that IN, which is soluble in IM NaCl, precipitates at the low
salt concentrations in the cleavage/integration reaction. The
reaction mixture was centrifuged after incubation and the fraction
of radioactive DNA that coprecipitated with IN was determined.
Without competition more than 50% of the DNA coprecipitated,
whereas in the reactions with a 20-fold excess of specific as well
as aspecific competitor hardly any radioactive DNA was found
in the pellet (figure SC). The ratio of cleaved product to uncleaved
substrate was not similar in pellet and supernatant: the pellet
contained a larger proportion of cleaved product than the
supernatant (figure SC lanes 3 and 4). This effect is stronger in
the presence of competitor (figure SC lanes 5- 16): only a little
bit of radioactive substrate DNA coprecipitated with IN, but a
large proportion of that was cleaved, whereas in the supernatant
almost no cleaved product was observed. Apparently, although
the binding of IN to substrate is functional, nevertheless the
binding is outcompeted by aspecific DNA. This provides a third
confirmation that IN does not bind with strong preference to viral
DNA termini.
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Figure 6. Kinetics of binding. 0.05 pmoles of HIV-1 U5 substrate were incubated
with 3 pmoles of HIV-2 IN for 0 (lanes 1 and 2), 5 (lanes 3 and 4), 18 (lanes
5 and 6), 35 (lanes 7 and 8) or 60 minutes (lanes 9 and 10). Reaction mixtures
were centrifuged for 5 minutes at 10,000 xg. Lanes labeled 'S' contain supematants
and lanes labeled 'P' contain pellets. Samples were separated on a 12% denaturing
polyacrylamide gel.
We determined how fast IN binds to DNA. In a time course
of the precipitation reaction we found, that already after 5 minutes
a large fraction of the DNA coprecipitated. The amount of
coprecipitated DNA did not increase much in the next 55 minutes
(figure 6). However, the amount of cleaved product increased
in time, especially in the precipitate. We interpret these results
as follows: as shown above most IN protein binds to DNA with
little sequence specificity within a few minutes. This is probably
an irreversible reaction under these reaction conditions. IN
quickly forms aggregates that can be pelleted by centrifugation,
but nevertheless it remains active for over an hour in cutting and
integration of viral DNA sequences that are bound to it. This
hypothesis would imply that competitor DNA only competes in
the cleavage reaction if it is added before all active IN is bound
to DNA. The cleavage reaction is indeed hardly affected by
addition of specific as well as aspecific competitor 5 minutes after
the addition of substrate (data not shown), whereas there is a
strong effect when competitor is added simultaneously with
substrate and an even stronger effect when the competitor is added
before the substrate. We conclude, that IN rapidly binds to DNA
without much specificity and that subsequently the viral DNA
ends are slowly and specifically cleaved.
DISCUSSION
We overexpressed the IN proteins of HIV- 1 and HIV-2 in E. coli
and purified them. The IN proteins can mediate both specific
cleavage of HIV DNA ends and integration of viral DNA. The
fact that IN, partially purified from various sources such as
bacteria, insect cells and vertebrate cells, could mediate
integration, suggested that IN is the only protein required for
integration. We show here that indeed pure HIV-2 IN is sufficient
for the reaction. The availability of pure and active HIV IN allows
studies of the reaction mechanism and kinetics, as well as
structure/function analysis of the protein.
We have not yet been able to determine whether the donor
cleavage and integration reactions are enzymatic, since the
reaction reaches a plateau long before one substrate molecule
per IN molecule has been converted into product, probably as
a result of aggregation of IN. This problem might be solved by
cross-linking IN to a matrix to stabilize it or by making a fusion
protein that is active and better soluble than IN.
One of our purposes in purifying HIV-2 as well as HIV- 1 IN
was to investigate a possible preference of each protein for the
corresponding viral DNA substrates. This could have allowed
mapping of the domain of IN responsible for viral DNA
recognition by domain swapping. We found however, that the
IN proteins of HIV-1 and HIV-2 (differing 43% in sequence)
act on both HIV- 1 and HIV-2 DNA with comparable efficiency.
We even observed a low level of specific cutting of a MoMLV
substrate. The corresponding opposite observation has also been
made: MoMLV IN integrates DNA substrates with HIV DNA
ends, albeit with low efficiency (13, 18). From the results
presented here we conclude that IN can recognize a wide range
of substrates with similarity to viral DNA ends. An extensive
analysis of HIV- 1 IN substrate requirements by mutagenesis of
viral DNA sequences resulted in a similar conclusion (17).
We found no specific DNA binding of IN in mobility shift
assays, nor did we see any specificity if we isolated aggregated
IN by centrifugation and determined whether viral DNA was
bound preferentially. In the latter case we know the interaction
between IN and substrate was productive, because a large
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proportion of the substrate DNA that was bound was cut within
an hour; nevertheless this binding of substrate to IN could be
competed out by aspecific DNA. Together with the observation
that addition of competitor DNA after a short preincubation with
the labeled DNA hardly affects the extent of cleavage, this leads
to the following picture of IN action in vitro: in reaction buffer
(under near physiological salt concentrations) IN quickly binds
to nucleic acids with little sequence specificity (and also
aggregates). Once bound to DNA, IN can slowly cut a specific
viral sequence. It probably remains bound to the cleaved DNA
and can mediate integration into target DNA. If IN does not find
a specific site it also remains bound. This picture of IN action
in vitro probably does not reflect the mechanism of recognition
of viral DNA in vivo: in the infected cell IN is in constant
proximity of HIV RNA, or, after reverse transcription, of HIV
DNA, in the viral core particle. This suggests that IN is probably
never free in solution; it may be bound first to viral RNA and
later to viral DNA, which can explain why IN does not need
to be very soluble under physiological salt concentrations. The
presence of IN in core particles can also explain its loose substrate
specificity. IN is probably continuously present near the viral
DNA, and it only needs to recognize the specific sequence for
precise positioning. This requires a specificity of another order
of magnitude than e.g. the specific recognition of enhancers in
a cellular genome by transcription factors.
In light of these results it is not easy to understand the
observations of others who reported specific binding by
recombinant MoMLV or HIV IN (27, 29). The HIV IN
preparations that showed specific DNA binding were not pure,
and no speAific cutting or integration by these protein preparations
was reported. Using pure and active HIV IN we find competition
of any binding by aspecific DNA, and this is consistent with our
observations that also cutting and integration of specific substrates
is competed out by aspecific DNA. Whatever the explanation
is for the band shifts observed by others, specific DNA binding
does not seem to be an intrinsic property of active HIV IN.
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